What Does Minerals Technologies Inc.'s (NYSE:MTX) Share Price Indicate?

Minerals Technologies Inc. (NYSE:MTX), which is in the chemicals business, and is based in United States, led the NYSE gainers with a relatively large price hike in the past couple of weeks. With many analysts covering the stock, we may expect any price-sensitive announcements have already been factored into the stock’s share price. However, what if the stock is still a bargain? Let’s examine Minerals Technologies’s valuation and outlook in more detail to determine if there’s still a bargain opportunity.

See our latest analysis for Minerals Technologies

Advertisement

What's the opportunity in Minerals Technologies?

The stock seems fairly valued at the moment according to my valuation model. It’s trading around 13.62% above my intrinsic value, which means if you buy Minerals Technologies today, you’d be paying a relatively reasonable price for it. And if you believe the company’s true value is $48.70, there’s only an insignificant downside when the price falls to its real value. Is there another opportunity to buy low in the future? Since Minerals Technologies’s share price is quite volatile, we could potentially see it sink lower (or rise higher) in the future, giving us another chance to buy. This is based on its high beta, which is a good indicator for how much the stock moves relative to the rest of the market.

What does the future of Minerals Technologies look like?

NYSE:MTX Past and Future Earnings, September 16th 2019
NYSE:MTX Past and Future Earnings, September 16th 2019

Investors looking for growth in their portfolio may want to consider the prospects of a company before buying its shares. Although value investors would argue that it’s the intrinsic value relative to the price that matter the most, a more compelling investment thesis would be high growth potential at a cheap price. Minerals Technologies’s earnings growth are expected to be in the teens in the upcoming years, indicating a solid future ahead. This should lead to robust cash flows, feeding into a higher share value.

What this means for you:

Are you a shareholder? It seems like the market has already priced in MTX’s positive outlook, with shares trading around its fair value. However, there are also other important factors which we haven’t considered today, such as the track record of its management team. Have these factors changed since the last time you looked at the stock? Will you have enough confidence to invest in the company should the price drop below its fair value?

Are you a potential investor? If you’ve been keeping tabs on MTX, now may not be the most advantageous time to buy, given it is trading around its fair value. However, the positive outlook is encouraging for the company, which means it’s worth diving deeper into other factors such as the strength of its balance sheet, in order to take advantage of the next price drop.

Price is just the tip of the iceberg. Dig deeper into what truly matters – the fundamentals – before you make a decision on Minerals Technologies. You can find everything you need to know about Minerals Technologies in the latest infographic research report. If you are no longer interested in Minerals Technologies, you can use our free platform to see my list of over 50 other stocks with a high growth potential.

We aim to bring you long-term focused research analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.

If you spot an error that warrants correction, please contact the editor at editorial-team@simplywallst.com. This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Simply Wall St has no position in the stocks mentioned. Thank you for reading.

About NYSE:MTX

Minerals Technologies

Develops, produces, and markets various mineral, mineral-based products and services.

Very undervalued with excellent balance sheet.

Advertisement

Weekly Picks

CE
Ceazar
SPAI logo
Ceazar on Sparc AI ·

When GPS fails: this small cap is fixing a $54B drone problem

Fair Value:CA$5.2554.7% undervalued
110 users have followed this narrative
0 users have commented on this narrative
24 users have liked this narrative
BL
BlackGoat
IREN logo
BlackGoat on IREN ·

IREN's Bold Moves in Sustainable Bitcoin Mining & AI Data Centers

Fair Value:US$71.4859.0% undervalued
213 users have followed this narrative
8 users have commented on this narrative
32 users have liked this narrative
HE
HedgeY
ARM logo
HedgeY on Arm Holdings ·

The Architecture Layer of AI Computing - But Priced Like the Future Already Arrived?

Fair Value:US$43047.7% undervalued
20 users have followed this narrative
1 users have commented on this narrative
6 users have liked this narrative
HI
Hidden_Rock_Capital
FISV logo
Hidden_Rock_Capital on Fiserv ·

Temporary "perfect storm" leads to opportunity to buy financial services leader for less than 5x long-term earnings

Fair Value:US$119.9953.6% undervalued
26 users have followed this narrative
0 users have commented on this narrative
9 users have liked this narrative

Updated Narratives

TH
TheGrayWolf_80
SCHD logo
TheGrayWolf_80 on Schwab Strategic Trust - Schwab U.S. Dividend Equity ETF ·

Building a 75/15/10 Income Machine with Schwab's Dividend ETF

Fair Value:US$63.7546.9% undervalued
0 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative
SI
MSFT logo
simplydunno on Microsoft ·

Microsoft's Capex Bill Comes Due Before the AI Revenue Does

Fair Value:US$512.123.7% undervalued
2 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative
HE
NGXGROUP logo
Henrynuke03 on Nigerian Exchange Group ·

Future Growth Awaits NGXGROUP with New High-Profile Listings

Fair Value:₦221.1732.3% undervalued
7 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative

Popular Narratives

OS
oscargarcia
NVDA logo
oscargarcia on NVIDIA ·

The company that went from selling GPUs to gamers to becoming the AI arms dealer of the 21st century.

Fair Value:US$28032.1% undervalued
211 users have followed this narrative
9 users have commented on this narrative
15 users have liked this narrative
CU
MSFT logo
CubanEros on Microsoft ·

A wonderful business at reasonable price.

Fair Value:US$419.917.0% undervalued
97 users have followed this narrative
0 users have commented on this narrative
7 users have liked this narrative
BE
PYPL logo
benjamin_lvieq on PayPal Holdings ·

PayPal: PayPal Doesn't Need to Grow – It Needs to Stop Falling – A Mispriced Cash Machine With a Cannibal Buyback

Fair Value:US$6510.2% undervalued
74 users have followed this narrative
2 users have commented on this narrative
11 users have liked this narrative

Trending Discussion

DE
TDOC logo
derek_3wsdg on Teladoc Health ·

You’ve overlooked the activist investor factor. Travis Cocke’s Voss has announced 5% ownership through a 13G filing. They’ve added to that 5% since, and in doing so, have created a structural trap door for 27.42 Million Shares actively sold short. Chuck will announce lots of positives on July 29 but it’s what Voss announces shortly after that will rock the overextended Teledoc shorts. The Walmart partnership is the tip of the iceberg. The market is missing the sheer regulatory and enterprise friction of modern corporate healthcare. Teladoc isn't a "consumer app"; it is the primary digital infrastructure integrated directly into the legacy backends of Tier-1 insurance companies and fortune 500 employers, covering 105 million+ lives. Teladoc is acting as the digital top-of-funnel engine for the world's largest retailer. If Voss pushes the narrative that Teladoc is effectively the outsourced digital brain of Walmart's entire healthcare footprint, the fair value shifts from a basic health multiple to an enterprise distribution premium. Additionally , we are in a structural gold rush for high-quality, legally compliant, longitudinal medical data to train vertical healthcare AI models. Large technology hyperscalers and pharmaceutical giants cannot simply scrape the internet for this; they need structured clinical inputs. Teladoc sits on one of the largest de-identified virtual medical datasets on earth. From the activist playbook , we’ll see Voss demand the immediate creation of a Data & Diagnostics Licensing Division, transforming a legacy liability into an incredibly high-margin, pure-software data asset that requires zero human clinician hours to scale. Chuck is doing great work and deserves credi5 for the Teledoc turnaround but it will be Travis Cocke who will be responsible for a share price way beyond your $15 valuation.

1
|
0